WeVote

Bill

Bill

H 4898

An Act relative to dual diagnosis treatment coverage

194th Legislature (2025-2026) Introduced by Jamie Eldridge and 1 co-sponsor

Requires coverage of up to 14 days per episode for integrated dual diagnosis treatment (substance use + mental health) with no preauthorization.

Committee recommended bill ought to pass and referred to the committee on House Ways and Means
0
WeVote Research Nonpartisan
Bill Summary · H 4898

Summary of H 4898 (194th) – An Act relative to dual diagnosis treatment coverage

intent and purpose
- The bill aims to ensure and standardize insurance coverage for comprehensive dual diagnosis treatment services. Specifically, it requires state-regulated and private health plans to cover integrated treatment for individuals with co-occurring substance use disorders and mental health conditions.
- Coverage is mandated to be without preauthorization for defined services and for up to a total of 14 days of care per episode, with certain administrative conditions (timely notification, initial treatment plan, and possible utilization review starting on day 7).

Key provisions and changes

1) Definitions of key services
- Acute treatment services: 24-hour medically supervised addiction treatment in a medically managed or medically monitored inpatient facility. Services may include evaluation, withdrawal management, biopsychosocial assessment, individual and group counseling, psychoeducational groups, and discharge planning.
- Clinical stabilization services: 24-hour clinically managed post-detoxification treatment, typically after acute treatment, focusing on education, relapse prevention, and aftercare planning.
- Co-occurring treatment services: inpatient detoxification provided in an inpatient psychiatric facility or unit, licensed by the Department of Mental Health.

2) Coverage requirements (three core elements repeated across multiple chapters)
- Providers must cover medically necessary acute treatment services, clinical stabilization services, and co-occurring treatment services for up to a total of 14 days per episode.
- No preauthorization is required for obtaining these services.
- Facilities must notify the carrier of admission and the initial treatment plan within 48 hours of admission.
- Utilization review procedures may be initiated starting on day 7 of treatment.
- Medical necessity is determined by the treating clinician in consultation with the patient and documented in the medical record.
- The bill also ensures coverage for substance use disorder evaluations ordered under section 511/2 of chapter 111 without preauthorization.

3) Applicability across multiple insurance regimes
- The amendments apply to:
- The Group Insurance Commission (GIC) for active and retired Commonwealth employees.
- Medicaid managed care organizations and related health plans administered through the Division of Insurance and the Department of Public Health.
- Individual and group health service plans, hospital service plans, and health maintenance organizations (HMOs) offered by insurers, as well as subscriber contracts under various health coverage regimes.
- The same 14-day coverage, notification, and no preauthorization structure applies to each of these contexts.

4) Administrative details
- The requirement to notify the carrier within 48 hours of admission and to initiate utilization review on day 7 is repeatedly codified across the bill’s sections.
- Medical necessity remains the determining standard, assessed by the treating clinician with patient input.

Affected parties

  • Individuals with dual diagnosis or co-occurring disorders seeking substance use and mental health treatment.
  • Insurers and providers offering inpatient/outpatient dual diagnosis services (hospitals, inpatient facilities, psychiatric units, managed care organizations, HMOs, and related vendor contracts).
  • State programs: GIC, Medicaid managed care entities, and health plans regulated under Massachusetts General Laws chapters 32A, 118E, 175, 176A, 176B, and related sections.

Timeline and status

  • Filed December 8, 2025; reported favorably by the Financial Services Committee and referred to Health Care Financing (January 8, 2026).
  • Committee action: Recommendation to pass; later referred to Ways and Means (April 15, 2026).

Impact

  • Promotes standardized access to essential dual diagnosis treatment for up to 14 days per episode without preauthorization.
  • Aims to reduce barriers to timely, integrated care and support continuity of treatment for individuals with co-occurring disorders.
  • Could affect premium costs and utilization management practices but seeks to simplify access through explicit provider and patient protections.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.